Forte Biosciences, Inc.是一家临床阶段的皮肤病学公司,致力于开发用于治疗炎症性皮肤病的活体生物疗法FB-401。 FB-401已完成对成人和儿童(3岁及以上)特应性皮炎患者的1/2a期测试。 对于安全和有效的疗法,特别是对于小儿特应性皮炎患者,存在大量的需求。Forte计划在2020年代中期将FB-401推进到2期临床试验中。
董事
名称
职位
Faheem Hasnain
Director and Chairman of the Board
Martin J. Duvall
Director and Chief Executive Officer
Harry E. Gruber
Director and President, Science and Innovation
David Parkinson
Director
Franklin M. Berger
Director
Lori Kunkel
Director
Paul Schimmel
Director
Thomas E. Darcy
Director
股东
名称
职位
Martin J. Duvall
Director and Chief Executive Officer
Asha Das
Senior Vice President and Chief Medical Officer
Mark Foletta
Executive Vice President and Chief Financial Officer
Douglas Jolly
Executive Vice President, Research and Pharmaceutical Development